Leerink Partnrs Brokers Reduce Earnings Estimates for Bruker

Bruker Corporation (NASDAQ:BRKR) – Investment analysts at Leerink Partnrs cut their Q2 2026 EPS estimates for Bruker in a report issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $0.45 for the quarter, down from their prior estimate of $0.51. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The company had revenue of $797.40 million for the quarter, compared to analysts’ expectations of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business’s revenue was down .4% compared to the same quarter last year. During the same period last year, the business posted $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS.

Other equities analysts have also issued reports about the stock. Wells Fargo & Company reduced their target price on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 5th. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the company a “hold” rating in a research note on Tuesday, August 5th. Bank of America dropped their price objective on shares of Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, June 26th. Citigroup dropped their price objective on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday, August 4th. Finally, Barclays dropped their price objective on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Five equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bruker currently has an average rating of “Hold” and an average price target of $51.00.

Bruker Stock Performance

Shares of NASDAQ:BRKR opened at $38.20 on Thursday. The firm has a market cap of $5.80 billion, a PE ratio of 73.46, a price-to-earnings-growth ratio of 5.07 and a beta of 1.20. The firm’s 50 day simple moving average is $33.35 and its 200-day simple moving average is $37.03. Bruker has a one year low of $28.53 and a one year high of $64.64. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, September 23rd. Bruker’s dividend payout ratio (DPR) is 38.46%.

Insiders Place Their Bets

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the sale, the director directly owned 18,016 shares in the company, valued at $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 27.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bruker

Several institutional investors have recently bought and sold shares of BRKR. Fifth Third Bancorp boosted its stake in Bruker by 54.2% in the first quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 390 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Bruker by 81.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 29,826 shares of the medical research company’s stock valued at $1,245,000 after acquiring an additional 13,367 shares in the last quarter. Rakuten Securities Inc. acquired a new stake in Bruker in the first quarter valued at approximately $167,000. Lecap Asset Management Ltd. acquired a new stake in Bruker in the first quarter valued at approximately $2,714,000. Finally, Wealthquest Corp acquired a new stake in Bruker in the first quarter valued at approximately $143,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.